Uso "off label" de Stents Coronarios Medicados: Factores pronósticos en el Seguimiento

background: the off label use of drug eluting stents (des) is associated to a greater risk of adverse events. aim: to determine predictors of major adverse cardiac events (mace) at one year after the off label implantation of des. method: an analysis of a cohort obtained from an institutional ptca registry was performed. adults who had one or more des implanted on off label indications were included. a multivariate model was developed in order to identify predictors of complications associated to off label use of des. results: 603 patients, mean age 60 years, 74% males, were included. after one year of follow up, mortality was 0.33%, st elevation mi developed in 3.0%, intra-stent thrombosis in 1.9% and revascularization of the target vessel was performed in 6.8%. dislipide-mia (or 2.2, [95% c.i. 1.2^.1]) and peripheral vascular disease (or 5.7, [2.0-16.2%]) were associated to a greater probability of mace. use of des in st elevation mi was associated to a decreased probability of mace (or 0.40, [0.17-0.95]). a reference vessel diameter <2.5mm (or 2.2 [0.8-6.1%]) or lesions >35 mm in length (or 0.99 [0.99-1.1]) were not predictive of mace. the same was true for other angiographic variables. conclusion: the use of des in off label indications was not associated to an increased development of mace. dislipidemia and peripheral vascular disease were independent predictors of mace.